论文部分内容阅读
目的探讨卡维地洛治疗老年充血性心力衰的疗效及安全性。方法将2009年7月～2011年9月于某院进行常规治疗的72例老年充血性心力衰竭患者设为对照组,同期的72例加用卡维地洛进行治疗的患者为观察组,后将两组患者的治疗总有效率、不良反应发生率及治疗前、治疗后1个月、2个月的心功能、血清BNP、hs-CRP水平进行对比。结果观察组不仅治疗总有效率及不良反应发生率明显好于对照组,且其治疗后的心功能、血清BNP、hs-CRP水平改善幅度也明显大于对照组,P均﹤0.05,差异有统计学意义。结论卡维地洛治疗老年充血性心力衰的临床疗效及安全性均受肯定,心功能及相关血清因子也从多个方面肯定了其疗效。
Objective To investigate the efficacy and safety of carvedilol in the treatment of senile congestive heart failure. Methods Seventy-two elderly patients with congestive heart failure undergoing routine treatment in a hospital from July 2009 to September 2011 were enrolled as the control group. During the same period, 72 patients treated with carvedilol were treated as observation group, The two groups of patients with total effective rate of adverse reactions and pretreatment, 1 month after treatment, 2 months of cardiac function, serum levels of BNP, hs-CRP were compared. Results The observation group was significantly better than the control group in the treatment of total effective rate and adverse reaction rate, and the improvement of cardiac function, serum BNP and hs-CRP levels were also significantly greater than the control group, P <0.05, the difference was statistically Significance of learning. Conclusion The efficacy and safety of carvedilol in the treatment of senile congestive heart failure are affirmed. Cardiac function and related serum factors have also confirmed its curative effect in many aspects.